Provided By PR Newswire
Last update: Mar 31, 2025
NEW YORK, March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read more at prnewswire.comNASDAQ:SRPT (4/22/2025, 2:55:50 PM)
58.29
+3.06 (+5.54%)
Find more stocks in the Stock Screener